Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ghiath Tayeb

Gastroenterology Rochester Hills, MI Medical Doctor

NPI 1447236401 CMS profile 292435

811 South Blvd E Ste 200, Rochester Hills, MI 48307

Open in the dashboard

General payments

$9,219

448 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ghiath Tayeb of Rochester Hills, MI is reported in the CMS Open Payments database as having received $9,219 across 448 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,382 98
2024 General $2,177 98
2023 General $1,455 67
2022 General $1,090 53
2021 General $669 33
2020 General $293 18
2019 General $1,154 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghiath Tayeb
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ghiath Tayeb were reported at $2,382. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ghiath Tayeb Gastroenterology median Middle half National median
2019 $1,154 $417 $126–$1,100 $163
2020 $293 $224 $74–$624 $114
2021 $669 $352 $106–$1,054 $132
2022 $1,090 $448 $129–$1,270 $149
2023 $1,455 $533 $150–$1,390 $160
2024 $2,177 $605 $160–$1,606 $164
2025 $2,382 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,661 119 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $987 71 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $612 36 payments
  4. Pfizer Inc. $573 35 payments
  5. Gilead Sciences, Inc. $565 23 payments
  6. Janssen Biotech, Inc. $432 23 payments
  7. Madrigal Pharmaceuticals $424 13 payments
  8. Regeneron Healthcare Solutions, Inc. $347 9 payments
  9. Celgene Corporation $274 19 payments
  10. Ardelyx, Inc. $262 13 payments
  11. Other $2,085 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,219 448 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,158 45 payments
  2. LINZESS $770 36 payments
  3. SKYRIZI Immunology $684 31 payments
  4. CREON $639 36 payments
  5. SKYRIZI Immunology $615 22 payments
  6. ENTYVIO $581 38 payments
  7. XELJANZ $497 32 payments
  8. STELARA $406 22 payments
  9. ZEPOSIA $396 20 payments
  10. XIFAXAN $392 20 payments
  11. Other $5,002 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

3,126

Median for Gastroenterology: 569

Drug cost

$323,467

Median for Gastroenterology: $104,976

Branded share of claims

16.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 153 $116,164
Xeljanz Tofacitinib Citrate Brand 13 $73,984
Ibsrela Tenapanor Hcl Brand 15 $33,965
Pentasa Mesalamine Brand 12 $24,655
Dexlansoprazole Dr Dexlansoprazole Brand 52 $13,350
Pantoprazole Sodium Generic 996 $11,243
Mesalamine Er Mesalamine Brand 31 $10,314
Mesalamine Generic 22 $7,419
Mesalamine Dr Mesalamine Brand 11 $5,249
Omeprazole Generic 432 $5,174

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$278,920

Medicare's payments for the services billed

Medicare patients

981

Average age 74

Services billed

3,055

546 women, 435 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 51%
Ischemic heart disease 48%
Chronic kidney disease 42%
Heart failure 33%
Atrial fibrillation 30%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $213
$213 — —
LINZESS
  • AbbVie, Inc. $150
  • Ironwood Pharmaceuticals, Inc $58
$208 153 —
SKYRIZI
  • AbbVie, Inc. $197
$197 — —
RINVOQ
  • AbbVie, Inc. $187
$187 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record